As a thermostatic shower mixer, Jaquar Qloud offers perfect regulation over temperature, water flow volume, and shower mode selection
Pfizer executives expressed measured optimism Tuesday over the prospect of providing a coronavirus vaccine in 2020 even as they signalled key data on the vaccine would not be released before the US election.
Pfizer Chief Executive Albert Bourla said the drug giant could supply some 40 million doses in the United States in 2020 if clinical testing proceeds as expected and regulators approve a vaccine.
"If all goes well, we will be ready to distribute an initial number of doses," said Bourla, who pointed to a US government contract for Pfizer to supply 40 million doses by the end of this year and 100 million doses by March 2021.
But Bourla said the company still had not reached key benchmarks in assessing vaccine efficacy.
Pfizer previously said it could have the data in October, which might have advanced the process ahead of the November 3 presidential election.
"We have reached the last mile here," Bourla said. "So let's all have the patience that's required for something so important for public health and the global economy."
He said the company expects to file for emergency use authorisation for its Covid-19 vaccine in the third week of November, roughly in line with earlier timetables.
Asked if he was "bullish" the vaccine would work, Bourla said: "I'm cautiously optimistic that the vaccine will work."
- Dip in doctor visits -
Pfizer reported a 71 per cent drop in profit to $2.2 billion in the latest quarter. However, the comparable period last year included a large gain connected to a transaction.
Revenues dipped four percent to $12.1 billion, missing analyst estimates.
Pfizer estimated a revenue hit of $500 million connected to Covid-19 due to lower pharma demand in China and fewer wellness visits by US patients.
The company saw an 11 percent drop in its hospital business in emerging markets, primarily due to fewer elective surgeries in China and shorter in-patient hospital stays in the country.
This effect was partially offset by increased demand for the Prevnar-13 vaccine for pneumonia "resulting from greater vaccine awareness for respiratory illnesses," the company said.
Pfizer also cited strong performance in its biopharma business due to good sales for cancer drug Ibrance, anticoagulant Eliquis and other medications.
Rival drugmaker Merck also is working on coronavirus vaccines, but the company is at an earlier phase compared with Pfizer.
Merck said one coronavirus vaccine candidate had entered phase 1 development and a second candidate would reach that stage shortly.
Merck reported a 55 per cent jump in quarterly earnings to $2.9 billion on a one percent rise in revenues to $12.6 billion.
Shares of Pfizer fell 1.3 per cent to $37.43, while Merck shed 1.1 percent to $77.99.
As a thermostatic shower mixer, Jaquar Qloud offers perfect regulation over temperature, water flow volume, and shower mode selection
The England star smashed nine sixes and eight fours in his 48-ball 108 as the Kings eclipsed the previous record set by South Africa who overhauled a target of 258 by the West Indies in 2023
Fatima was diagnosed with autoimmune hepatitis, a condition where the body's immune system attacks liver cells
The announcement follows a difficult spell for the royal family after both Charles and his daughter-in-law Catherine, revealed that they had cancer
It reiterated that pilgrims require a Haj visa and it can be obtained through recognised official channels
The 18-year-old was taken to hospital in a serious condition
The brothers, who say they are innocent, are accused of having formed an organised criminal network in early 2021 in Romania, as well as in the US and Britain
The left-handed batter scored 3369 runs in 136 one-day internationals and 2893 in 140 Twenty20 internationals — both Pakistan records